IMR Press / EJGO / Volume 31 / Issue 2 / pii/1630984569293-1477946674

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
Expression and significance of β-catenin, Glut-1 and PTEN in proliferative endometrium, endometrial intraepithelial neoplasia and endometrioid adenocarcinoma
Show Less
1 Department of Gynecological Oncology, Zhongnan Hospital, Wuhan University, Wuhan (China)
Eur. J. Gynaecol. Oncol. 2010, 31(2), 160–164;
Published: 10 April 2010
Abstract

Objective: The aim of this study was to explore the potentiality of β-catenin, Glut-1 and PTEN proteins as markers for a diagnosis of endometrial intraepithelial neoplasia (EIN). Design: Ten proliferative endometrium, 83 endometrial hyperplasia (59 benign hyperplasia, 24 EIN) and 24 endometrioid adenocarcinoma sections were immunostained for β-catenin, Glut-1 and PTEN protein expression. Results: (1) Abnormal expression of β-catenin was detected in 10% of benign hyperplasia, 50% of EIN and 67% of endometrioid adenocarcinoma. (2) Overexpression of Glut-1 was present in 58% of EIN and 71% of endometrioid adenocarcinoma. (3) Complete loss of PTEN immunoreactivity was found in 20% of proliferative endometrium, 29% of benign hyperplasia, 38% of EIN and 63% of endometrioid adenocarcinoma. Conclusions: The abnormal expression of β-catenin and overexpression of Glut-1 may be useful markers in distinguishing benign hyperplasia from EIN, whereas lack of PTEN expression is not an appropriate marker for a diagnosis of EIN.
Keywords
β-catenin
Glut-1
PTEN
Benign endometrial hyperplasia
EIN
Endometrioid adenocarcinoma
Share
Back to top